Citius Pharmaceuticals Inc (CTXR)
Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
outlays were on the rise at the company in the most recent fiscal period
company announced fourth quarter of 2022 operating deficit of $-7.549566 million
Published Dec 23 2022
CSIMarket Team / CSIMarket.com
The Major Pharmaceutical Preparations sector veterans start to analyze the fourth quarter of 2022 numbers. Presently those veterans monitor operating deficit of $-7.549566 million, from the CTXR, as it hasn't cited any revenue yet, for the respective July to September 30 2022 reporting period.
The small company hasn't declared the respective revenue yet, but in order to insert current results into context. This is done by measuring with company's achievement through the fourth quarter of 2021, where the CTXR announced an operating deficit of $-5.203243 million.
The CEO is seeking various business models, in order to assure steady business. Over the same period the shortfalls, that the CTXR has endured all along the developing span, have extended to $-7.991 million, from $-4.961 million, relative to the corresponding period a year ago.
Citius Pharmaceuticals Inc is expected to report next financial results on May 11, 2023.
The small company hasn't declared the respective revenue yet, but in order to insert current results into context. This is done by measuring with company's achievement through the fourth quarter of 2021, where the CTXR announced an operating deficit of $-5.203243 million.
The CEO is seeking various business models, in order to assure steady business. Over the same period the shortfalls, that the CTXR has endured all along the developing span, have extended to $-7.991 million, from $-4.961 million, relative to the corresponding period a year ago.
Citius Pharmaceuticals Inc is expected to report next financial results on May 11, 2023.